TURNOVER (x1000 NOK)
NET PROFIT (x1000 NOK)
EMPLOYEES
Novo Nordisk Pharmatech A/S
Closing information (x1000 NOK)
Closing information | 2023/12 | 2022/12 | 2021/12 |
Turnover |
1,327,835
|
846,870
|
830,309 |
Earnings before taxes |
148,848
|
69,723
|
196,763 |
Total assets |
1,910,252
|
1,368,708
|
858,260 |
Current assets |
954,577
|
713,031
|
331,305 |
Current liabilities |
691,438
|
331,564
|
121,430 |
Equity capital |
1,156,671
|
976,185
|
697,751 |
- share capital |
15,084
|
14,157
|
13,412 |
Employees (average) |
150
![]() |
150
![]() |
150 |
Financial ratios
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Solvency |
60.6%
|
71.3%
|
81.3% |
Turnover per employee |
8,852
|
5,646
|
5,535 |
Profit as a percentage of turnover |
11.2%
|
8.2%
|
23.7% |
Return on assets (ROA) | |||
Current ratio |
138.1%
|
215.1%
|
272.8% |
Return on equity (ROE) |
12.9%
|
7.1%
|
28.2% |
Change turnover |
425,521
|
-29,469
|
-65,244 |
Change turnover % |
47%
|
-3%
|
-7% |
Chg. No. of employees |
0
![]() |
0
![]() |
0 |
Chg. No. of employees % |
0%
![]() |
0%
![]() |
0% |
Total value of public sale
Fiscal year | 2023/12 | 2022/12 | 2021/12 |
Total value of public sale |
0
![]() |
0
![]() |
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.